Epidemiological Characteristics of KRAS G12C Mutations in Chinese Pan-Cancer and Novel Targeted Protein Degradation Therapeutic Strategies
The RAS gene family is the most common oncogene in human cancers, encoding proteins that act as critical molecular switches regulating cell proliferation and survival signaling pathways.
- Recent Advances
I. Research Background and Clinical Significance of KRAS G12C Mutation
The RAS gene family is the most common oncogene in human cancers, encoding proteins that act as critical molecular switches regulating cell proliferation and survival signaling pathways. Among them, KRAS mutations are the most prevalent, long considered "undruggable" due to their protein structural characteristics. This dilemma changed with breakthroughs in covalent inhibitors targeting the specific mutant KRAS G12C (such as AMG 510, MRTX849, etc.), marking a new era in KRAS-targeted therapy. The KRAS G12C mutation (glycine at position 12 replaced by cysteine) accounts for approximately 12% of all KRAS mutations, providing a structural basis for designing selective inhibitors. Clarifying the epidemiological characteristics of this mutation in the Chinese population is crucial for developing precision medicine strategies.
II. Panoramic Analysis of KRAS G12C Mutation in the Chinese Population: Research Methods and Key Findings
A study published in Translational Lung Cancer Research systematically depicted the distribution panorama of KRAS G12C mutations by performing next-generation sequencing (NGS, using the YuanSu YS450 gene panel) on 11,951 multicenter tumor samples from China. The main findings are as follows:
1. Overall Mutation Frequency: In all pan-cancer samples, the KRAS mutation rate was 16.6% (1,978/11,951). Among these, KRAS G12C mutations accounted for 14.5% of all KRAS mutations and 2.4% of the total study population.
2. Tumor-Specific Distribution: KRAS G12C mutations exhibited significant tumor heterogeneity. The highest mutation rate was observed in non-small cell lung cancer (especially lung adenocarcinoma, 4.3%), followed by colorectal cancer (2.5%) and biliary tract cancer (2.3%). This mutation was also detected in other cancers such as pancreatic and gastric cancers but at lower frequencies.
3. Co-Mutation Spectrum: The vast majority (99.6%) of KRAS G12C-mutant tumors harbored other genomic alterations. The most common co-mutated genes included TP53 (54.7%), LRP1B (37.0%), and FAT3 (25.1%). Additionally, some cases showed co-mutations in RAS/RTK pathway-related genes (e.g., BRAF, PIK3CA), which may be associated with acquired resistance mechanisms to targeted therapies.
4. Correlation with Smoking: In the lung cancer subgroup analysis, KRAS mutations (including G12C) in lung adenocarcinoma patients were positively correlated with smoking history, consistent with known epidemiological features.
This study is the first large-scale revelation of real-world data on KRAS G12C mutations in Chinese cancer patients, providing critical evidence for patient identification and clinical trial design targeting this mutation subgroup.
III. Beyond Traditional Inhibition: KRAS G12C Protein Degradation Targeting Chimera Strategy
Despite the milestone achievements of small-molecule inhibitors, their clinical application still faces challenges of primary or acquired resistance. Protein degradation targeting chimera (PROTAC) technology offers an innovative approach to address this issue. The KRAS[G12C]/CRBN PROTAC Kit is a cutting-edge research tool developed based on this strategy.
| Key Points | Detailed Explanation |
|---|---|
| 1. Mechanism of Action | The bifunctional molecule in this kit specifically binds to the mutant KRAS G12C protein at one end and recruits the E3 ubiquitin ligase CRL4CRBN (with CRBN as its substrate receptor) at the other. By forming a ternary complex, it induces polyubiquitination of KRAS G12C, leading to its degradation by the proteasome. |
| 2. Advantages Over Inhibitors | - Fundamentally Different Mode of Action: Traditional inhibitors aim to block KRAS G12C activity, while PROTAC aims to completely eliminate the mutant protein, potentially more thoroughly terminating all its oncogenic signaling functions. - Potential to Overcome Resistance: For resistance caused by upstream reactivation or bypass signaling, degrading the target protein may be more effective than inhibiting its activity. - Targeting "Non-Catalytic" Functions: PROTAC does not rely on inhibiting kinase activity and thus may target other oncogenic roles of KRAS, such as its scaffolding function. |
| 3. Research and Application Value | Using the KRAS[G12C]/CRBN PROTAC Kit, researchers can directly validate the feasibility and efficiency of degrading KRAS G12C protein and its effects on downstream signaling pathways (e.g., MAPK/ERK), cancer cell viability, and proliferation in cellular and preclinical models. This provides novel candidate molecules and proof-of-concept for developing next-generation therapies targeting KRAS G12C. |
IV. Conclusions and Prospects
Although the overall incidence of KRAS G12C mutations in Chinese cancer patients is relatively low, they represent a clear therapeutic need subgroup in specific cancers such as lung and colorectal cancers. With the success of small-molecule inhibitors, this target has completely moved beyond its "undruggable" history. However, the treatment landscape is still rapidly evolving. Protein degradation strategies represented by PROTAC technology, especially tools like the KRAS[G12C]/CRBN PROTAC Kit that recruit the CRBN E3 ligase system, are opening an innovative R&D path beyond traditional inhibition. In the future, combining precise mutation screening with novel mechanism-based therapies is expected to bring more durable and effective treatment options for KRAS G12C-mutant patients.
V. Which Manufacturers Provide the KRAS[G12C]/CRBN PROTAC Kit?
The TR-FRET Human KRAS[G12C]/CRBN PROTAC Binding Kit (Catalog No.: UA086001), independently developed by Nanjing U-Protein, is a high-performance detection platform based on advanced time-resolved fluorescence energy transfer (TR-FRET) technology. It is specifically designed for the accurate quantification of ternary complex formation between KRAS[G12C] mutant protein and CRBN E3 ubiquitin ligase mediated by PROTAC molecules. This kit provides a sensitive, rapid, and homogeneous in vitro detection solution for the development of protein degradation therapies, drug screening, and mechanism research targeting the challenging KRAS G12C.
| Core Advantages of the Product |
|---|
| High Sensitivity and Low Background Noise: Utilizing TR-FRET detection technology, time-resolved and dual-wavelength detection effectively reduces sample autofluorescence and compound interference, significantly improving the signal-to-noise ratio, especially for high-precision analysis of low-abundance ternary complexes. |
| Simulation of Physiological Ternary Complex Conformation: The kit provides rigorously validated high-purity, high-activity human KRAS[G12C] mutant protein and CRBN complex, both maintaining correct spatial conformation and complete biological functions, accurately simulating the assembly process of PROTAC-induced target protein-E3 ligase ternary complexes. |
| Homogeneous Detection and Operational Convenience: The "mix-incubate-detect" homogeneous operation mode eliminates washing steps, simplifies the workflow, and is compatible with automated workstations, supporting high-throughput screening and significantly improving experimental efficiency. |
| Excellent Stability and Batch-to-Batch Consistency: Advanced recombinant expression systems and strict quality control processes ensure high purity, superior long-term stability, and outstanding batch-to-batch consistency, providing reliable support for long-term continuous drug screening and mechanism research. |
| Complete Solution and Professional Support: We provide detailed optimized experimental protocols, standard curve examples, result interpretation guidelines, and professional technical support for various application needs such as PROTAC molecule screening, linker optimization, and degradation activity correlation analysis. |
Nanjing U-Protein is committed to providing cutting-edge, high-quality core reagents and tools for challenging targets in protein degradation, precision cancer therapy, and innovative drug development. For detailed technical information, validation data, or specific application inquiries regarding the TR-FRET Human KRAS[G12C]/CRBN PROTAC Binding Kit (Catalog No.: UA086001), please feel free to contact us.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 